title: A review of relative dose intensity and survival in patients with metastatic solid tumors.
abstract: Studies have shown that in the curative setting patients with cancer receiving chemotherapy at higher relative dose intensity (RDI) had better clinical outcomes than those receiving treatment at lower RDI. However, the impact of RDI in advanced/metastatic disease remains unclear. A review of the literature was performed to evaluate the relationship between RDI and survival in patients with metastatic lung, breast, or ovarian cancer receiving chemotherapy. Few studies attempted to specifically associate RDI with survival in a systematic way. Findings from studies that analyzed overall survival with a prespecified RDI threshold support the emerging perception that maintaining an RDI≥85% has a favorable impact on survival. Nonetheless, these studies were limited by their retrospective nature. More studies are needed to further evaluate the impact of maintaining planned chemotherapy dose intensity on outcomes in metastatic solid tumors.
authors.affiliation: Division of Gynecology Oncology, Duke University Medical Center, Durham, NC, USA; Duke Cancer Institute, Durham, NC, USA.
authors.forename: Laura J
authors.initials: LJ
authors.lastname: Havrilesky
authors.affiliation: Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA.
authors.forename: Maureen
authors.initials: M
authors.lastname: Reiner
authors.affiliation: Hematology/Oncology, Amgen Inc., Thousand Oaks, CA, USA.
authors.forename: Phuong Khanh
authors.initials: PK
authors.lastname: Morrow
authors.affiliation: Hematology/Oncology, Amgen Inc., Thousand Oaks, CA, USA.
authors.forename: Holly
authors.initials: H
authors.lastname: Watson
authors.affiliation: Duke Cancer Institute, Durham, NC, USA; Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA. Electronic address: jeffrey.a.crawford@duke.edu.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Crawford
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
keywords: Breast cancer; Lung cancer; Metastatic disease; Outcomes; Ovarian cancer; Relative dose intensity; Survival